Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Plasma cell 1Dermatologic 1

Conditions

Lymphoma 27Lymphoma, Non-Hodgkin 24Leukemia, Lymphocytic, Chronic, B-Cell 24Lymphoma, Mantle-Cell 23Lymphoma, Follicular 17Lymphoma, Large B-Cell, Diffuse 15Multiple Myeloma 14Recurrence 13Hodgkin Disease 12Lymphoma, B-Cell, Marginal Zone 7Leukemia 7Waldenstrom Macroglobulinemia 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Neoplasms, Plasma Cell 4Neoplasms 4Leukemia, B-Cell 4Hematologic Neoplasms 4Myeloproliferative Disorders 3Myelodysplastic Syndromes 3Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell 3Lymphoma, B-Cell 3Leukemia, Myeloid, Acute 3Leukemia, Lymphoid 3Small Cell Lung Carcinoma 2Leukemia, Biphenotypic, Acute 2Burkitt Lymphoma 2Sezary Syndrome 1Sarcoma 1Renal Insufficiency, Chronic 1

Interventions

Cyclophosphamide 108Rituximab 62Etoposide 56Methotrexate 52Cytarabine 52Peripheral Blood Stem Cell Transplantation 47Vincristine 45Filgrastim 43fludarabine phosphate 41Radiotherapy 37Mycophenolic Acid 35Doxorubicin 35Tacrolimus 33Busulfan 33Whole-Body Irradiation 32Prednisone 31Methylprednisolone 27Antilymphocyte Serum 27Dexamethasone 26Cyclosporine 26Melphalan 24merphos 20blinatumomab 20Leucovorin 20Granulocyte Colony-Stimulating Factor 16Carmustine 15fludarabine 14Ifosfamide 14Calcium Dobesilate 14CT-P10 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Burkitt Lymphoma × Bendamustine Hydrochloride × Clear all
NCT03856216 2026-04-15

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

M.D. Anderson Cancer Center

Phase 2 Terminated
15 enrolled 11 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01110135 2017-05-24

Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

University of Washington

Phase 2 Completed
43 enrolled 5 charts
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡